Misaki Yoshida, Satoshi Hara, Ryo Nishioka, Takafumi Kobayashi, Yuya Murase, Hideharu Kimura, Ichiro Mizushima, Mitsuhiro Kawano
Internal medicine (Tokyo, Japan) 2024 Jul 15Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs). There are a few case reports of remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE) as an irAE. We herein report a 49-year-old Japanese man who developed acute-onset polyarthralgia and edema of the back of both hands and bilateral lower legs after pembrolizumab administration for lung cancer. The patient's lung cancer was in complete remission, leading to the diagnosis of RS3PE induced by pembrolizumab rather than malignancy. When patients show RS3PE during ICI treatment, rheumatologists should consider the possibility of an irAE after excluding malignancy and systemic diseases.
Misaki Yoshida, Satoshi Hara, Ryo Nishioka, Takafumi Kobayashi, Yuya Murase, Hideharu Kimura, Ichiro Mizushima, Mitsuhiro Kawano. Development of Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome with Pembrolizumab for Lung Squamous Cell Carcinoma. Internal medicine (Tokyo, Japan). 2024 Jul 15;63(14):2089-2096
PMID: 38072406
View Full Text